Raymond James & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$120K	–	3932
2023 Q2	$120K	Buy	+1,000	New	+$129K	﹤0.01%	3592
2023 Q1	–	Sell	-9,300	Closed	-$259K	–	4061
2022 Q4	$259K	Buy	+9,300	New	+$1.08M	﹤0.01%	3307
2022 Q3	–	Sell	-10,500	Closed	-$47K	–	4129
2022 Q2	$47K	Hold	10,500	–	–	﹤0.01%	3796
2022 Q1	$76K	Sell	10,500 -10,500	-50%	-$804K	﹤0.01%	3870
2021 Q4	$261K	Sell	21,000 -34,500	-62%	-$2.95M	﹤0.01%	3531
2021 Q3	$697K	Buy	55,500 +37,000	+200%	+$2.85M	﹤0.01%	2820
2021 Q2	$144K	Hold	18,500	–	–	﹤0.01%	3768
2021 Q1	$181K	Sell	18,500 -26,400	-59%	-$2.44M	﹤0.01%	3644
2020 Q4	$2.56M	Sell	44,900 -100	-0.2%	-$14.8K	﹤0.01%	1751
2020 Q3	$900K	Sell	45,000 -200	-0.4%	-$30.4K	﹤0.01%	2239
2020 Q2	$1.74M	Hold	45,200	–	–	﹤0.01%	1820
2020 Q1	$443K	Sell	45,200 -1,000	-2%	-$114K	﹤0.01%	2497
2019 Q4	$1.13M	Buy	46,200 +2,000	+5%	+$202K	﹤0.01%	2196
2019 Q3	$155K	Sell	44,200 -2,800	-6%	-$331K	﹤0.01%	3331
2019 Q2	$1.96M	Buy	+47,000	New	+$5.71M	﹤0.01%	1819

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James & Associates's SRPT Position: Q3 2024 in Review

Raymond James & Associates increased its Sarepta Therapeutics (SRPT) stake by 19% in Q3 2024, buying an estimated $562K and bringing the position to 25,713 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Raymond James & Associates first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $6.13M in Q4 2020. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Raymond James & Associates held 25,713 shares of Sarepta Therapeutics worth $3.21M as of Q3 2024.
Raymond James & Associates bought 4,065 Sarepta Therapeutics shares in Q3 2024, an estimated $562K.
Sarepta Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1928 holding.
Raymond James & Associates first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
Raymond James & Associates's Sarepta Therapeutics position peaked at $6.13M in Q4 2020.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.